<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Exp Ther Med</journal-id><journal-id journal-id-type="iso-abbrev">Exp Ther Med</journal-id><journal-id journal-id-type="publisher-id">ETM</journal-id><journal-title-group><journal-title>Experimental and Therapeutic Medicine</journal-title></journal-title-group><issn pub-type="ppub">1792-0981</issn><issn pub-type="epub">1792-1015</issn><publisher><publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27446307</article-id><article-id pub-id-type="pmc">4950288</article-id><article-id pub-id-type="doi">10.3892/etm.2016.3363</article-id><article-id pub-id-type="publisher-id">ETM-0-0-3363</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Clinical effects of carvedilol and trimetazidine for the treatmentof alcoholic myocardiopathy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Li</surname><given-names>Hui</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-3363"/></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Fu-Yuan</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-3363"/><xref rid="c1-etm-0-0-3363" ref-type="corresp"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Xiao-Lan</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-3363"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Xiao-Mei</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-3363"/></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Lei</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-3363"/></contrib></contrib-group><aff id="af1-etm-0-0-3363">Department of Cardiovascularology, Xiangyang Hospital Affiliated to Hubei University of Medicine, Xiangyang, Hubei 441001, P.R. China</aff><author-notes><corresp id="c1-etm-0-0-3363"><italic>Correspondence to</italic>: Dr Fu-Yuan Liu, Department of Cardiovascularology, Xiangyang Hospital Affiliated to Hubei University of Medicine, 15 Jiefang Road, Xiangyang, Hubei 441000, P.R. China, E-mail: <email>lfy0053@163.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>8</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>19</day><month>5</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>19</day><month>5</month><year>2016</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>12</volume><issue>2</issue><fpage>979</fpage><lpage>982</lpage><history><date date-type="received"><day>04</day><month>3</month><year>2016</year></date><date date-type="accepted"><day>19</day><month>5</month><year>2016</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Li et al.</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license></permissions><abstract><p>The aim of the study was to compare the clinical effects of carvedilol and trimetazidine for the treatment of alcoholic cardiomyopathy. A total of 60 patients diagnosed with alcoholic cardiomyopathy were enrolled in the study. The patients were randomly divided into the carvedilol (n=20), trimetazidine (n=20) and control (n=20) groups. The patients in the control, carvedilol and trimetazidine groups were treated with conventional drugs, conventional drugs + carvedil and conventional drugs + trimetazidine respectively, for 12 weeks. The patients were compared for their heart functions [left ventricular ejection fraction (LVEF), C-reactive protein (CRP) and 6 min walking], heart rate, blood pressure and heart enlargement (cardiothoracic proportion and left ventricular diameter) before and after treatment. The parameters studied for heart functions, heart rate, blood pressure, heart enlargement, clinical effects before and after treatment were statistically insignificant (p&#x0003e;0.05). After treatment, the carvedilol and trimetazidine groups showed higher LVEF and CRP, longer walking distance in 6 min, as well as lower heart rate and blood pressure (both systolic and diastolic) compared to the control group. Similarly, the cardiothoracic proportion and left ventricular internal diameter for the carvedilol and trimetazidine groups was lower than those of the control group, with better clinical effects (p&#x0003c;0.05). In conclusion, the curative effects of the carvedilol and trimetazidine groups of alcoholic myocardiopathy similar. Both are safe agents that may improve the cardiac function and heart expansion of patients.</p></abstract><kwd-group><kwd>carvedilol</kwd><kwd>trimetazidine</kwd><kwd>alcoholic myocardiopathy</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Alcoholic cardiomyopathy is a type of myocardial degeneration resulting from a large amount of alcohol consumption with varied clinical manifestations such as cardiac enlargement, cardiac insufficiency and arrhythmia, which mainly occurs in the 30- to 50-year age group (<xref rid="b1-etm-0-0-3363" ref-type="bibr">1</xref>,<xref rid="b2-etm-0-0-3363" ref-type="bibr">2</xref>). In recent years, with improvement of the standard of living and changes of lifestyle, the number of heavy drinking in China has been increasing rapidly, which is inevitably leading to enhanced risks of alcoholic cardiomyopathy (<xref rid="b3-etm-0-0-3363" ref-type="bibr">3</xref>). Patients with relatively milder symptoms may gradually recover following discontinuation of alcohol consumption.</p><p>In the present study, 60 patients with alcoholic cardiomyopathy at the Department of Cardiovascularology, Xiangyang Hospital (Hubei, China) were selected and the clinical effects of the treatment of carvedilol and trimetazidine were compared.</p></sec><sec sec-type="subjects|methods"><title>Patients and methods</title><sec><title/><sec><title>Patients</title><p>Sixty patients, diagnosed with alcoholic cardiomyopathy at the Department of Cardiovascularology, Xiangyang Hospital were selected between March 2012 and July 2014. The patients conformed to the clinical diagnostic criteria. The patients were randomly divided the patients into the carvedilol (n=20), trimetazidine (n=20) and control (n=20) groups. The carvedilol group included 17 men and 3 women with an age range of 31&#x02013;64 years and an average age of 45.8&#x000b1;4.6 years. Alcohol consumption for this group was 8.1&#x02013;18.6 years with an average of 12.2&#x000b1;3.9 years, and the cardiac functional grading for 13 and 7 cases was grade II and III, respectively. The trimetazidine group included 16 men and 4 women with an age range of 30&#x02013;65 years and an average of 46.8&#x000b1;4.2 years. Alcohol consumption for this group was 7.8&#x02013;19.0 years with an average of 11.9&#x000b1;3.6 years, and the cardiac functional grading for 14 and 6 cases was grade II and III, respectively. The control group included 18 men and 2 women with an age range of 33&#x02013;64 years and an average of 46.6&#x000b1;4.3 years. Alcohol consumption for this group was 746.6&#x000b1;4.3 years with an average of 11.3&#x000b1;3.3 years, and cardiac functional grading for 15 and 5 cases was grade II and III level, respectively. Differences in gender, age, alcohol consumption years and cardiac functional grading of the three groups were not statistically significant (p&#x0003e;0.05).</p></sec><sec><title>Inclusion and exclusion criteria</title><p>Inclusion criteria for the study were: i) History of long-term (&#x02265;6 years) heavy consumption of alcohol or bibulosity; ii) heart failure and cardiac enlargement and other symptoms; iii) amount of alcohold consumed for men was &#x0003e;80 g/day, and women was &#x0003e;40 g/day; and iv) agreed with the study and provided written informed consent.</p><p>Exclusion criteria for the study were: i) Patients with other heart diseases; ii) patients who disagreed with the study, or had a drinking temperance &#x0003c;6 months; and iii) patients with incomplete clinical data.</p><p>The present study was approved by the Ethics Committee of Xiangyang Hospital.</p></sec><sec><title>Treatment methods</title><p>The patients in the control group were administered conventional drugs, including digoxin, diuretics, angiotensin-converting enzyme inhibitor (ACEI) and spironolactone, and cardiac color ultrasound and chest X-ray examinations were performed. The changes of pulmonary rates, blood pressure and heart rate were observed daily, electrocardiographic examination was performed once every three days and the patients were suggested to discontinue consumption of alcohol and take a good rest.</p><p>The patients in the carvedilol group were administered conventional drugs and carvedilol, initial dose of 6.25 mg/time, twice per day orally. If patients tolerated the dose, the systolic blood pressure was measured in erect position 1 h following drug treatment, and the dose was maintained for 7&#x02013;14 days, which was subsequently increased to 12.5 mg/time, twice per day orally.</p><p>For the trimetazidine group, the patients were administered with conventional drugs and trimetazidin. The dosage regimen was 20 mg/time, three times per day after a meal.</p></sec><sec><title>Observation indices</title><p>The heart functions [left ventricular ejection fraction (LVEF), C-reactive protein (CRP), and 6-min walking distance], heart rate, blood pressure (systolic pressure and diastolic pressure) and heart enlargement (cardiothoracic proportion and left ventricular diameter) were compared for the three groups prior to and after treatment.</p></sec><sec><title>Curative effects assessment standard</title><p>Excellence was considered when cardiac function was improved by &#x02265;2 levels. Effective was considered when cardiac function was improved by 1 level. Ineffective was considered when cardiac function was not improved or even deteriorated.</p></sec><sec><title>Statistical analysis</title><p>SPSS 15.0 statistical software (SPSS 15.0 statistical software (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Data were presented as mean &#x000b1; standard deviation. The comparison among groups was made by variance analysis. The pair-wise comparison was made by using the q-test. Enumeration data were tested by using the &#x003c7;<sup>2</sup> test, ranked data were tested using the rank-sum test. Difference was of statistical significance in case of the bilateral p&#x0003c;0.05.</p></sec></sec></sec><sec sec-type="results"><title>Results</title><sec><title/><sec><title>Comparison of cardiac function indices prior to and after treatment</title><p>Prior to treatment, LVEF, CRP, and 6-min walking distance of the three groups were not statistically different (p&#x0003e;0.05). Following treatment, the differences of LVEF, CRP, and 6-min walking distance of the three groups were statistically different (p&#x0003c;0.05). In comparison to the control group, the carvedilol and trimetazidine groups showed significant improvement in LVEF and CRP and the 6-min walking distance (p&#x0003c;0.05). However, the differences between the carvedilol and trimetazidine groups were not statistically significant (p&#x0003e;0.05) (<xref rid="tI-etm-0-0-3363" ref-type="table">Table I</xref>).</p></sec><sec><title>Comparison of heart rate and blood pressure prior to and after treatment</title><p>Prior to treatment, the heart rate, blood pressure (systolic and diastolic) of the three groups were not statistically different (p&#x0003e;0.05). Following treatment, the differences of heart rate, blood pressure (systolic and diastolic) of the three groups were statistically different (p&#x0003c;0.05). The heart rate, blood pressure (systolic and diastolic) of the carvedilol and trimetazidine groups were significantly lower than those of the control groups (p&#x0003c;0.05). However, differences between the carvedilol and trimetazidine groups were not statistically significant (p&#x0003e;0.05) (<xref rid="tII-etm-0-0-3363" ref-type="table">Table II</xref>).</p></sec><sec><title>Comparison of cardiac enlargement indices prior to and after treatment</title><p>Prior to treatment, the cardiothoracic proportion and left ventricular internal diameter of the three groups were not statistically different (p&#x0003e;0.05). Following treatment, differences of cardiothoracic proportion and left ventricular internal diameter of the three groups were statistically different (p&#x0003c;0.05). The cardiothoracic proportion and left ventricular internal diameter of the carvedilol and trimetazidine groups were significantly higher than those of the control group (p&#x0003c;0.05). However, the differences between the carvedilol and trimetazidine groups were not statistically significant (p&#x0003e;0.05) (<xref rid="tIII-etm-0-0-3363" ref-type="table">Table III</xref>).</p></sec><sec><title>Comparison of clinical effects</title><p>Differences of clinical effects of the three groups were statistically different. The clinical effects of the carvedilol and trimetazidine groups were significantly improved compared to the control group (p&#x0003c;0.05). On the other hand, the differences between the carvedilol and trimetazidine groups were not statistically significant (p&#x0003e;0.05) (<xref rid="tIV-etm-0-0-3363" ref-type="table">Table IV</xref>). In addition, there were no obvious adverse reactions in any of the three groups.</p></sec></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Alcoholic myocardiopathy is a type of non-ischemic dilated cardiomyopathy caused by long-term alcohol consumption (<xref rid="b4-etm-0-0-3363" ref-type="bibr">4</xref>). The mechanisms by which ethanol can induce cardiomyopathy include destruction of the integrity of myocardial cell membrane and effects on ion exchange and information transfer of various cardiac muscle cells; functional change of mitochondria and other organelles, leading to shortage of myocardial energy; abnormal fat deposition and changes of activity of ATP and inhibition of myocardial activity; imbalance of nutrition and aggravation of myocardial damages (<xref rid="b5-etm-0-0-3363" ref-type="bibr">5</xref>&#x02013;<xref rid="b7-etm-0-0-3363" ref-type="bibr">7</xref>). In addition, ethanol can also seriously affect the permeability of ions, leading to loss of potassium phosphate and calcium overload, which further inhibits the contraction and relaxation of myocardium. The clinical manifestations of alcoholic cardiomyopathy are diverse, mainly including arrhythmia, heart failure and cardiac insufficiency. Alcoholic myocardiopathy mainly occurs in men and accounts for 90% (<xref rid="b8-etm-0-0-3363" ref-type="bibr">8</xref>). The study by Schwarz <italic>et al</italic> (<xref rid="b9-etm-0-0-3363" ref-type="bibr">9</xref>) showed that alcoholic cardiomyopathy accounted for approximately 1/3 of dilated cardiomyopathy.</p><p>Patients with relatively milder symptoms may gradually recover following discontinuation of alcohol consumption. However, a patient with severe symptoms should accept drug treatment. Common drugs include diuretics, digitalis, angiectasis drugs, ACEI, &#x003b2;-blockers, hypokalemia and hypomagnesemia (<xref rid="b10-etm-0-0-3363" ref-type="bibr">10</xref>,<xref rid="b11-etm-0-0-3363" ref-type="bibr">11</xref>). Carvedilol is a &#x003b2;-blocker that may block the receptors and relax vessels. Trimetazidine is an anti-ischemic drug used for optimizing myocardial energy metabolism, which may affect the metabolism of myocardial cells, improve tissue tolerance to hypoxia and eliminate oxygen-free radicals (<xref rid="b12-etm-0-0-3363" ref-type="bibr">12</xref>). In the present study, carvedilol and trimetazidine were used to treat alcoholic myocardiopathy. The results strongly suggest the benefits of carvedilol and trimetazidine for the treatment of alcohol-induced myocardiopathy. In comparison to the control groups, the treated groups showed significantly higher LVEF and CRP, farther 6-min walking distance, lower heart rate and blood pressure (systolic and diastolic), lower cardiothoracic proportion and left ventricular internal diameter, along with better clinical effects. A comparison of the above indicators between the carvedilol and trimetazidine groups revealed that differences were statistically non-significant, indicating that the curative effects of carvedilol and trimetazidine for the treatment of alcoholic myocardiopathy were similar. The results were consistent with earlier studies of Duan <italic>et al</italic> (<xref rid="b13-etm-0-0-3363" ref-type="bibr">13</xref>) and Dijkstra <italic>et al</italic> (<xref rid="b14-etm-0-0-3363" ref-type="bibr">14</xref>), indicating that carvedilol and trimetazidine were capable of improving cardiac function and heart expansion without associated risk.</p></sec></body><back><ref-list><title>References</title><ref id="b1-etm-0-0-3363"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kollar</surname><given-names>J</given-names></name></person-group><article-title>[Clinical picture of alcoholic myocardiopathy. Review]</article-title><source>Vnitr Lek</source><volume>18</volume><fpage>172</fpage><lpage>181</lpage><year>1972</year><pub-id pub-id-type="pmid">4551713</pub-id></element-citation></ref><ref id="b2-etm-0-0-3363"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mamas</surname><given-names>MA</given-names></name><name><surname>Deaton</surname><given-names>C</given-names></name><name><surname>Rutter</surname><given-names>MK</given-names></name><name><surname>Yuille</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>SG</given-names></name><name><surname>Ray</surname><given-names>SG</given-names></name><name><surname>New</surname><given-names>J</given-names></name><name><surname>Gibson</surname><given-names>JM</given-names></name><name><surname>Neyses</surname><given-names>L</given-names></name></person-group><article-title>Impaired glucose tolerance and insulin resistance in heart failure: underrecognized and undertreated?</article-title><source>J Card Fail</source><volume>16</volume><fpage>761</fpage><lpage>768</lpage><year>2010</year><pub-id pub-id-type="doi">10.1016/j.cardfail.2010.05.027</pub-id><pub-id pub-id-type="pmid">20797600</pub-id></element-citation></ref><ref id="b3-etm-0-0-3363"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jun</surname><given-names>H</given-names></name><name><surname>Bo</surname><given-names>Y</given-names></name></person-group><article-title>New progress in the pathogenesis of alcoholic cardiomyopathy</article-title><source>Chin J Evid-Based Cardiovasc Med</source><volume>6</volume><fpage>236</fpage><lpage>237</lpage><year>2014</year><comment>(In Chinese)</comment></element-citation></ref><ref id="b4-etm-0-0-3363"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Estruch</surname><given-names>RR</given-names></name></person-group><article-title>[Alcoholic myocardiopathy]</article-title><source>Rev Clin Esp</source><volume>201</volume><fpage>137</fpage><lpage>139</lpage><year>2001</year><pub-id pub-id-type="pmid">11387823</pub-id></element-citation></ref><ref id="b5-etm-0-0-3363"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugihara</surname><given-names>K</given-names></name><name><surname>Fujimoto</surname><given-names>S</given-names></name><name><surname>Motomiya</surname><given-names>Y</given-names></name><name><surname>Hashimoto</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>S</given-names></name><name><surname>Dohi</surname><given-names>K</given-names></name></person-group><article-title>Usefulness of long axis M-mode echocardiographic measurements for optimum dialysis in patients on maintenance hemodialysis: comparison with changes in plasma levels of atrial natriuretic peptide and brain natriuretic peptide</article-title><source>Clin Nephrol</source><volume>56</volume><fpage>140</fpage><lpage>149</lpage><year>2001</year><pub-id pub-id-type="pmid">11522091</pub-id></element-citation></ref><ref id="b6-etm-0-0-3363"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gvozdjak</surname><given-names>A</given-names></name><name><surname>Bada</surname><given-names>V</given-names></name><name><surname>Kruty</surname><given-names>F</given-names></name><name><surname>Niderland</surname><given-names>TR</given-names></name><name><surname>Gvozdjak</surname><given-names>J</given-names></name></person-group><article-title>[Mechanism of the development of cardiac insufficiency in alcoholic myocardiopathy]</article-title><source>Kardiologiia</source><volume>16</volume><fpage>136</fpage><lpage>137</lpage><year>1976</year><pub-id pub-id-type="pmid">1018418</pub-id></element-citation></ref><ref id="b7-etm-0-0-3363"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahfoudh-Boussaid</surname><given-names>A</given-names></name><name><surname>Hadj</surname><given-names>Ayed Tka K</given-names></name><name><surname>Zaouali</surname><given-names>MA</given-names></name><name><surname>Rosell&#x000f3;-Catafau</surname><given-names>J</given-names></name><name><surname>Ben Abdennebi</surname><given-names>H</given-names></name></person-group><article-title>Effects of trimetazidine on the Akt/eNOS signaling pathway and oxidative stress in an in vivo rat model of renal ischemia-reperfusion</article-title><source>Ren Fail</source><volume>36</volume><fpage>1436</fpage><lpage>1442</lpage><year>2014</year><pub-id pub-id-type="doi">10.3109/0886022X.2014.949765</pub-id><pub-id pub-id-type="pmid">25246344</pub-id></element-citation></ref><ref id="b8-etm-0-0-3363"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name></person-group><article-title>Effects of capsule on cardiac functions and expression of HMGB1 of patients with dilated cardiomyopathy</article-title><source>Chin J Evid-Based Cardiovasc Med</source><volume>6</volume><fpage>271</fpage><lpage>273</lpage><year>2014</year><comment>(In Chinese)</comment></element-citation></ref><ref id="b9-etm-0-0-3363"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwarz</surname><given-names>F</given-names></name><name><surname>Mall</surname><given-names>G</given-names></name><name><surname>Zebe</surname><given-names>H</given-names></name><name><surname>Schmitzer</surname><given-names>E</given-names></name><name><surname>Manthey</surname><given-names>J</given-names></name><name><surname>Scheurlen</surname><given-names>H</given-names></name><name><surname>K&#x000fc;bler</surname><given-names>W</given-names></name></person-group><article-title>Determinants of survival in patients with congestive cardiomyopathy: quantitative morphologic findings and left ventricular hemodynamics</article-title><source>Circulation</source><volume>70</volume><fpage>923</fpage><lpage>928</lpage><year>1984</year><pub-id pub-id-type="doi">10.1161/01.CIR.70.6.923</pub-id><pub-id pub-id-type="pmid">6499148</pub-id></element-citation></ref><ref id="b10-etm-0-0-3363"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arranz</surname><given-names>CJ</given-names></name><name><surname>Lopez</surname><given-names>JL</given-names></name><name><surname>Moya</surname><given-names>MM</given-names></name><name><surname>Martin</surname><given-names>JT</given-names></name></person-group><article-title>[Reversibility of alcoholic myocardiopathy]</article-title><source>Med Clin (Barc)</source><volume>93</volume><fpage>316</fpage><lpage>317</lpage><year>1989</year><pub-id pub-id-type="pmid">2607838</pub-id></element-citation></ref><ref id="b11-etm-0-0-3363"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>CM</given-names></name><name><surname>Almsherqi</surname><given-names>ZA</given-names></name><name><surname>McLachlan</surname><given-names>CS</given-names></name><name><surname>Matthews</surname><given-names>S</given-names></name><name><surname>Ramachandran</surname><given-names>M</given-names></name><name><surname>Tay</surname><given-names>SK</given-names></name><name><surname>Deng</surname><given-names>Y</given-names></name></person-group><article-title>Acute starvation in C57BL/6J mice increases myocardial UCP2 and UCP3 protein expression levels and decreases mitochondrial bio-energetic function</article-title><source>Stress</source><volume>14</volume><fpage>66</fpage><lpage>72</lpage><year>2011</year><pub-id pub-id-type="doi">10.3109/10253890.2010.506931</pub-id><pub-id pub-id-type="pmid">20932228</pub-id></element-citation></ref><ref id="b12-etm-0-0-3363"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aubert</surname><given-names>A</given-names></name><name><surname>Bernard</surname><given-names>C</given-names></name><name><surname>Clauser</surname><given-names>P</given-names></name><name><surname>Harpey</surname><given-names>C</given-names></name><name><surname>Vaudry</surname><given-names>H</given-names></name></person-group><article-title>[A cellular anti-ischemic agent, trimetazidine prevents the deleterious effects of oxygen free-radicals on the internal ear]</article-title><source>Ann Otolaryngol Chir Cervicofac</source><volume>107</volume><fpage>28</fpage><lpage>35</lpage><year>1990</year><comment>(In French)</comment><pub-id pub-id-type="pmid">2240996</pub-id></element-citation></ref><ref id="b13-etm-0-0-3363"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>G</given-names></name></person-group><article-title>The effect of coenzyme Q10 combined with trimetazidine for treatment of elderly patients with alcoholic cardiomyopathy heart failure</article-title><source>Chin J Gerontol</source><volume>32</volume><fpage>4379</fpage><lpage>4381</lpage><year>2012</year></element-citation></ref><ref id="b14-etm-0-0-3363"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dijkstra</surname><given-names>AF</given-names></name><name><surname>Verdonk</surname><given-names>P</given-names></name><name><surname>Lagro-Janssen</surname><given-names>AL</given-names></name></person-group><article-title>Gender bias in medical textbooks: examples from coronary heart disease, depression, alcohol abuse and pharmacology</article-title><source>Med Educ</source><volume>42</volume><fpage>1021</fpage><lpage>1028</lpage><year>2008</year><pub-id pub-id-type="doi">10.1111/j.1365-2923.2008.03150.x</pub-id><pub-id pub-id-type="pmid">18761614</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="tI-etm-0-0-3363" orientation="portrait" position="float"><label>Table I.</label><caption><p>Comparison of cardiac function indexes before and after treatment (mean &#x000b1; SD).</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th align="center" valign="bottom" colspan="2" rowspan="1">LVEF (%)</th><th align="center" valign="bottom" colspan="2" rowspan="1">CRP (mg/l)</th><th align="center" valign="bottom" colspan="2" rowspan="1">6-min walking distance (m)</th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th align="center" valign="bottom" colspan="2" rowspan="1"><hr/></th><th align="center" valign="bottom" colspan="2" rowspan="1"><hr/></th><th align="center" valign="bottom" colspan="2" rowspan="1"><hr/></th></tr><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Group</th><th align="center" valign="bottom" rowspan="1" colspan="1">Case</th><th align="center" valign="bottom" rowspan="1" colspan="1">Pre-treatment</th><th align="center" valign="bottom" rowspan="1" colspan="1">Post-treatment</th><th align="center" valign="bottom" rowspan="1" colspan="1">Pre-treatment</th><th align="center" valign="bottom" rowspan="1" colspan="1">Post-treatment</th><th align="center" valign="bottom" rowspan="1" colspan="1">Pre-treatment</th><th align="center" valign="bottom" rowspan="1" colspan="1">Post-treatment</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="center" valign="top" rowspan="1" colspan="1">20</td><td align="center" valign="top" rowspan="1" colspan="1">37.4&#x000b1;8.2</td><td align="center" valign="top" rowspan="1" colspan="1">41.4&#x000b1;7.9</td><td align="center" valign="top" rowspan="1" colspan="1">12.3&#x000b1;1.3</td><td align="center" valign="top" rowspan="1" colspan="1">8.8&#x000b1;0.9</td><td align="center" valign="top" rowspan="1" colspan="1">300.7&#x000b1;46.3</td><td align="center" valign="top" rowspan="1" colspan="1">474.8&#x000b1;58.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Carvedilol</td><td align="center" valign="top" rowspan="1" colspan="1">20</td><td align="center" valign="top" rowspan="1" colspan="1">36.9&#x000b1;9.1</td><td align="center" valign="top" rowspan="1" colspan="1">44.8&#x000b1;7.9<sup><xref rid="tfn2-etm-0-0-3363" ref-type="table-fn">a</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">12.3&#x000b1;1.3</td><td align="center" valign="top" rowspan="1" colspan="1">5.1&#x000b1;0.6<sup><xref rid="tfn2-etm-0-0-3363" ref-type="table-fn">a</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">298.9&#x000b1;45.1</td><td align="center" valign="top" rowspan="1" colspan="1">540.7&#x000b1;48.2<sup><xref rid="tfn2-etm-0-0-3363" ref-type="table-fn">a</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Trimetazidine</td><td align="center" valign="top" rowspan="1" colspan="1">20</td><td align="center" valign="top" rowspan="1" colspan="1">36.8&#x000b1;8.5</td><td align="center" valign="top" rowspan="1" colspan="1">45.2&#x000b1;8.2<sup><xref rid="tfn2-etm-0-0-3363" ref-type="table-fn">a</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">12.3&#x000b1;1.3</td><td align="center" valign="top" rowspan="1" colspan="1">5.3&#x000b1;0.7<sup><xref rid="tfn2-etm-0-0-3363" ref-type="table-fn">a</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">298.9&#x000b1;45.1</td><td align="center" valign="top" rowspan="1" colspan="1">546.4&#x000b1;69.4<sup><xref rid="tfn2-etm-0-0-3363" ref-type="table-fn">a</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">F</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.642</td><td align="center" valign="top" rowspan="1" colspan="1">3.714</td><td align="center" valign="top" rowspan="1" colspan="1">0.000</td><td align="center" valign="top" rowspan="1" colspan="1">6.732</td><td align="center" valign="top" rowspan="1" colspan="1">1.246</td><td align="center" valign="top" rowspan="1" colspan="1">11.484</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">P-value</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.05</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-etm-0-0-3363"><p>LVEF, left ventricular ejection fraction; CRP, C-reactive protein. Compared with the control group</p></fn><fn id="tfn2-etm-0-0-3363"><label>a</label><p>P&#x0003c;0.05.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tII-etm-0-0-3363" orientation="portrait" position="float"><label>Table II.</label><caption><p>Comparison of the heart rate and blood pressure prior to and after treatment (mean &#x000b1; SD).</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th align="center" valign="bottom" colspan="2" rowspan="1">Heart rate (times/min)</th><th align="center" valign="bottom" colspan="2" rowspan="1">Systolic pressure (mmHg)</th><th align="center" valign="bottom" colspan="2" rowspan="1">Diastolic pressure (mmHg)</th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th align="center" valign="bottom" colspan="2" rowspan="1"><hr/></th><th align="center" valign="bottom" colspan="2" rowspan="1"><hr/></th><th align="center" valign="bottom" colspan="2" rowspan="1"><hr/></th></tr><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Group</th><th align="center" valign="bottom" rowspan="1" colspan="1">Case</th><th align="center" valign="bottom" rowspan="1" colspan="1">Pre-treatment</th><th align="center" valign="bottom" rowspan="1" colspan="1">Post-treatment</th><th align="center" valign="bottom" rowspan="1" colspan="1">Pre-treatment</th><th align="center" valign="bottom" rowspan="1" colspan="1">Post-treatment</th><th align="center" valign="bottom" rowspan="1" colspan="1">Pre-treatment</th><th align="center" valign="bottom" rowspan="1" colspan="1">Post-treatment</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="center" valign="top" rowspan="1" colspan="1">20</td><td align="center" valign="top" rowspan="1" colspan="1">90&#x000b1;19</td><td align="center" valign="top" rowspan="1" colspan="1">86&#x000b1;18</td><td align="center" valign="top" rowspan="1" colspan="1">147&#x000b1;27</td><td align="center" valign="top" rowspan="1" colspan="1">137&#x000b1;69</td><td align="center" valign="top" rowspan="1" colspan="1">79&#x000b1;11</td><td align="center" valign="top" rowspan="1" colspan="1">74&#x000b1;10</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Carvedilol</td><td align="center" valign="top" rowspan="1" colspan="1">20</td><td align="center" valign="top" rowspan="1" colspan="1">89&#x000b1;18</td><td align="center" valign="top" rowspan="1" colspan="1">76&#x000b1;7<sup><xref rid="tfn4-etm-0-0-3363" ref-type="table-fn">a</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">149&#x000b1;26</td><td align="center" valign="top" rowspan="1" colspan="1">122&#x000b1;71<sup><xref rid="tfn4-etm-0-0-3363" ref-type="table-fn">a</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">78&#x000b1;10</td><td align="center" valign="top" rowspan="1" colspan="1">68&#x000b1;11<sup><xref rid="tfn4-etm-0-0-3363" ref-type="table-fn">a</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Trimetazidine</td><td align="center" valign="top" rowspan="1" colspan="1">20</td><td align="center" valign="top" rowspan="1" colspan="1">91&#x000b1;18</td><td align="center" valign="top" rowspan="1" colspan="1">75&#x000b1;8<sup><xref rid="tfn4-etm-0-0-3363" ref-type="table-fn">a</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">146&#x000b1;27</td><td align="center" valign="top" rowspan="1" colspan="1">120&#x000b1;71<sup><xref rid="tfn4-etm-0-0-3363" ref-type="table-fn">a</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">80&#x000b1;12</td><td align="center" valign="top" rowspan="1" colspan="1">65&#x000b1;10<sup><xref rid="tfn4-etm-0-0-3363" ref-type="table-fn">a</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">F</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.843</td><td align="center" valign="top" rowspan="1" colspan="1">7.241</td><td align="center" valign="top" rowspan="1" colspan="1">0.116</td><td align="center" valign="top" rowspan="1" colspan="1">5.384</td><td align="center" valign="top" rowspan="1" colspan="1">0.942</td><td align="center" valign="top" rowspan="1" colspan="1">4.926</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">P-value</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.05</td></tr></tbody></table><table-wrap-foot><fn id="tfn3-etm-0-0-3363"><p>1 mmHg=0.133 kPa; compared with the control group:</p></fn><fn id="tfn4-etm-0-0-3363"><label>a</label><p>p&#x0003c;0.05.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tIII-etm-0-0-3363" orientation="portrait" position="float"><label>Table III.</label><caption><p>Comparison of cardiac enlargement indices prior to and after treatment (mean &#x000b1; SD).</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th align="center" valign="bottom" colspan="2" rowspan="1">CTR (%)</th><th align="center" valign="bottom" colspan="2" rowspan="1">LVID (%)</th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th align="center" valign="bottom" colspan="2" rowspan="1"><hr/></th><th align="center" valign="bottom" colspan="2" rowspan="1"><hr/></th></tr><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Group</th><th align="center" valign="bottom" rowspan="1" colspan="1">Case</th><th align="center" valign="bottom" rowspan="1" colspan="1">Pre-treatment</th><th align="center" valign="bottom" rowspan="1" colspan="1">Post-treatment</th><th align="center" valign="bottom" rowspan="1" colspan="1">Pre-treatment</th><th align="center" valign="bottom" rowspan="1" colspan="1">Post-treatment</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="center" valign="top" rowspan="1" colspan="1">20</td><td align="center" valign="top" rowspan="1" colspan="1">0.68&#x000b1;0.11</td><td align="center" valign="top" rowspan="1" colspan="1">0.64&#x000b1;0.10</td><td align="center" valign="top" rowspan="1" colspan="1">58.8&#x000b1;0.7</td><td align="center" valign="top" rowspan="1" colspan="1">52.6&#x000b1;0.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Carvedilol</td><td align="center" valign="top" rowspan="1" colspan="1">20</td><td align="center" valign="top" rowspan="1" colspan="1">0.66&#x000b1;0.09</td><td align="center" valign="top" rowspan="1" colspan="1">0.55&#x000b1;0.12</td><td align="center" valign="top" rowspan="1" colspan="1">59.7&#x000b1;0.6</td><td align="center" valign="top" rowspan="1" colspan="1">46.5&#x000b1;0.8<sup><xref rid="tfn6-etm-0-0-3363" ref-type="table-fn">a</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Trimetazidine</td><td align="center" valign="top" rowspan="1" colspan="1">20</td><td align="center" valign="top" rowspan="1" colspan="1">0.71&#x000b1;0.13</td><td align="center" valign="top" rowspan="1" colspan="1">0.51&#x000b1;0.08</td><td align="center" valign="top" rowspan="1" colspan="1">59.2&#x000b1;0.7</td><td align="center" valign="top" rowspan="1" colspan="1">45.8&#x000b1;0.9<sup><xref rid="tfn6-etm-0-0-3363" ref-type="table-fn">a</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">F</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.347</td><td align="center" valign="top" rowspan="1" colspan="1">3.972</td><td align="center" valign="top" rowspan="1" colspan="1">0.142</td><td align="center" valign="top" rowspan="1" colspan="1">4.286</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">P-value</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.05</td></tr></tbody></table><table-wrap-foot><fn id="tfn5-etm-0-0-3363"><p>CTR, cardiothoracic. LVID, left ventricular internal diameter. Compared with the control group</p></fn><fn id="tfn6-etm-0-0-3363"><label>a</label><p>p&#x0003c;0.05.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tIV-etm-0-0-3363" orientation="portrait" position="float"><label>Table IV.</label><caption><p>Comparison of the clinical effects in different groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Group</th><th align="center" valign="bottom" rowspan="1" colspan="1">Case</th><th align="center" valign="bottom" rowspan="1" colspan="1">Excellence</th><th align="center" valign="bottom" rowspan="1" colspan="1">Effective</th><th align="center" valign="bottom" rowspan="1" colspan="1">Ineffective</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="center" valign="top" rowspan="1" colspan="1">20</td><td align="center" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;4</td><td align="center" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Carvedilol</td><td align="center" valign="top" rowspan="1" colspan="1">20</td><td align="center" valign="top" rowspan="1" colspan="1">11</td><td align="center" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="1" colspan="1">2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Trimetazidine</td><td align="center" valign="top" rowspan="1" colspan="1">20</td><td align="center" valign="top" rowspan="1" colspan="1">12</td><td align="center" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="1" colspan="1">1</td></tr></tbody></table></table-wrap></floats-group></article>